Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?

NCT ID NCT06703216

Not yet recruiting Disease control Sponsor: Kevin McNerney Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether giving the drug anakinra early can prevent severe cytokine release syndrome (CRS) in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) who are receiving CAR-T cell therapy. Participants receive anakinra at the first sign of fever, and the dose is increased if symptoms worsen. The goal is to see if this approach reduces the rate of severe CRS and other immune-related side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
the drug anakinra (Kineret®) given intravenously
What this could lead to
If successful, this approach could make CAR-T cell therapy safer by preventing severe cytokine release syndrome, a common and dangerous side effect.
What could go wrong
This is a small, early-phase pilot study with no comparison group, so results may not be definitive. Anakinra could also have side effects or fail to reduce severe CRS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell childhood acute lymphoblastic leukemia Burkitt lymphoma secondary hemophagocytic lymphohistiocytosis cytokine release syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B ACUTE LYMPHOBLASTIC LEUKEMIA CAR T CELL THERAPY CYTOKINE RELEASE SYNDROME IMMUNE EFFECTOR CELL ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY SYNDROME

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.